- Home
- ANAB vs PCRX Comparison
ANAB vs PCRX Comparison
Compare ANAB & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- PCRX
- Stock Information
- Founded
- ANAB 2005
- PCRX 2006
- Country
- ANAB United States
- PCRX United States
- Employees
- ANAB N/A
- PCRX N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- ANAB Health Care
- PCRX Health Care
- Exchange
- ANAB Nasdaq
- PCRX Nasdaq
- Market Cap
- ANAB 600.4M
- PCRX 604.7M
- IPO Year
- ANAB 2017
- PCRX 2011
- Fundamental
- Price
- ANAB $22.27
- PCRX $17.55
- Analyst Decision
- ANAB Buy
- PCRX Buy
- Analyst Count
- ANAB 11
- PCRX 10
- Target Price
- ANAB $54.64
- PCRX $26.60
- AVG Volume (30 Days)
- ANAB 623.5K
- PCRX 569.9K
- Earning Date
- ANAB 11-05-2024
- PCRX 11-06-2024
- Dividend Yield
- ANAB N/A
- PCRX N/A
- EPS Growth
- ANAB N/A
- PCRX N/A
- EPS
- ANAB N/A
- PCRX N/A
- Revenue
- ANAB $57,172,000.00
- PCRX $694,957,000.00
- Revenue This Year
- ANAB $207.49
- PCRX $4.59
- Revenue Next Year
- ANAB N/A
- PCRX N/A
- P/E Ratio
- ANAB N/A
- PCRX N/A
- Revenue Growth
- ANAB 282.17
- PCRX 4.40
- 52 Week Low
- ANAB $13.36
- PCRX $11.16
- 52 Week High
- ANAB $41.31
- PCRX $35.95
- Technical
- Relative Strength Index (RSI)
- ANAB 42.41
- PCRX 60.29
- Support Level
- ANAB $18.03
- PCRX $16.00
- Resistance Level
- ANAB $22.94
- PCRX $18.34
- Average True Range (ATR)
- ANAB 1.37
- PCRX 0.82
- MACD
- ANAB 0.45
- PCRX -0.01
- Stochastic Oscillator
- ANAB 86.18
- PCRX 66.24
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.